Alkermes (ALKS) Operating Leases (2019 - 2026)
Alkermes' (ALKS) quarterly Operating Leases came in at $63.7 million in Q1 2026, down 5.99% year-on-year from $67.8 million in Q1 2025, and up 0.78% on a QoQ basis from $63.3 million in Q4 2025.
Alkermes (ALKS) Operating Leases (2019 - 2026) Analysis & Trends
Alkermes (ALKS) has 8 years of Operating Leases data on file, last reported at $63.7 million in Q1 2026.
- On a quarterly basis, Operating Leases fell 5.99% year-over-year to $63.7 million in Q1 2026; TTM through Mar 2026 was $63.7 million, a 5.99% decrease from a year earlier, with the FY2025 full-year figure at $63.3 million, down 8.82% from the prior year.
- Operating Leases for Q1 2026 stood at $63.7 million, up from $63.3 million in the prior quarter.
- Over the last five years, Operating Leases for ALKS reached as high as $104.0 million in Q1 2022 and fell as low as $63.3 million in Q4 2025.
- Historically, Operating Leases has averaged $77.2 million across 5 years, with a median of $74.1 million in 2024.
- Across the five-year window, Operating Leases slipped 26.76% in 2022 and declined 0.76% in 2023, its largest moves.
- Year by year, Operating Leases stood at $76.3 million in 2022, then slipped by 0.76% to $75.7 million in 2023, then dropped by 8.37% to $69.4 million in 2024, then dropped by 8.82% to $63.3 million in 2025, then increased by 0.78% to $63.7 million in 2026.
- Per Business Quant data, the three most recent Operating Leases figures were $63.7 million in Q1 2026, $63.3 million in Q4 2025, and $65.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.75 Mn |
| Dec 31, 2025 | 63.25 Mn |
| Sep 30, 2025 | 64.97 Mn |
| Jun 30, 2025 | 66.22 Mn |
| Mar 31, 2025 | 67.81 Mn |
| Dec 31, 2024 | 69.37 Mn |
| Sep 30, 2024 | 71.03 Mn |
| Jun 30, 2024 | 72.54 Mn |
| Mar 31, 2024 | 74.10 Mn |
| Dec 31, 2023 | 75.71 Mn |
| Sep 30, 2023 | 78.55 Mn |
| Jun 30, 2023 | 82.34 Mn |
| Mar 31, 2023 | 86.11 Mn |
| Dec 31, 2022 | 76.29 Mn |
| Sep 30, 2022 | 95.73 Mn |
| Jun 30, 2022 | 99.83 Mn |
| Mar 31, 2022 | 104.01 Mn |
| Dec 31, 2021 | 104.16 Mn |
| Sep 30, 2021 | 107.86 Mn |
| Jun 30, 2021 | 111.66 Mn |